MedTrace Logo

REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification

NCT01252953 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30449

Last updated 2024-06-25

Study results available
· View outcomes & findings →

Summary

The Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL) trial aims to determine whether lipid modification with anacetrapib 100mg daily reduces the risk of coronary death, myocardial infarction (MI) or coronary revascularization (collectively known as major coronary events) in patients with circulatory problems who have their Low-density Lipoprotein (LDL) cholesterol level treated with a statin.

Conditions

Interventions

DRUG

Anacetrapib

tablet, 100mg daily

DRUG

Placebo anacetrapib

tablet, 1 tablet daily

Sponsors & Collaborators

Principal Investigators

  • Martin Landray · University of Oxford

  • Louise Bowman · University of Oxford

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-06-30
Primary Completion
2017-01-31
Completion
2037-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01252953 on ClinicalTrials.gov